Grifols (GIKLY) Non-Current Deferred Tax Liability (2010 - 2025)

Grifols (GIKLY) reported Non-Current Deferred Tax Liability of $1.0 billion for Q4 2025, down 7.32% on a YoY basis from $1.1 billion in Q4 2024, and down 7.32% quarter-over-quarter from $1.1 billion in Q4 2024.

Grifols (GIKLY) Non-Current Deferred Tax Liability (2010 - 2025) Analysis & Trends

Grifols has reported Non-Current Deferred Tax Liability for 16 years, with the latest figure at $1.0 billion in Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Deferred Tax Liability fell 7.32% year-over-year to $1.0 billion; the trailing twelve-month figure through Dec 2025 stood at $1.0 billion (down 7.32% YoY), and the FY2025 full-year result was $1.0 billion, down 7.32% from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 stood at $1.0 billion, down from $1.1 billion in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $1.1 billion in Q4 2024, with the low at $725.3 million in Q4 2021.
  • Historically, Non-Current Deferred Tax Liability has averaged $985.7 million across 5 years, with a median of $1.1 billion in 2022.
  • Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability soared 45.57% — and 2025, when it decreased 7.32%.
  • Grifols' Non-Current Deferred Tax Liability stood at $725.3 million in 2021, then surged by 45.57% to $1.1 billion in 2022, then gained by 0.75% to $1.1 billion in 2023, then advanced by 1.67% to $1.1 billion in 2024, then declined by 7.32% to $1.0 billion in 2025.
  • The last three Non-Current Deferred Tax Liability figures came in at $1.0 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.1 billion (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Grifols - - -

Historic Data

Download Data
DateValue
Dec 31, 2025 1.00 Bn
Dec 31, 2025 1.00 Bn
Dec 31, 2024 1.08 Bn
Dec 31, 2024 1.08 Bn
Dec 31, 2023 1.06 Bn
Dec 31, 2023 1.06 Bn
Dec 31, 2022 1.06 Bn
Dec 31, 2022 1.06 Bn
Dec 31, 2021 725.26 Mn
Dec 31, 2021 725.26 Mn
Dec 31, 2020 663.88 Mn
Dec 31, 2020 663.88 Mn
Dec 31, 2019 377.23 Mn
Dec 31, 2019 377.23 Mn
Dec 31, 2018 333.13 Mn
Dec 31, 2018 333.13 Mn
Jun 30, 2018 470.02 Mn
Jun 30, 2018 470.02 Mn
Dec 31, 2017 457.92 Mn
Dec 31, 2017 457.92 Mn